

Laurence Camoin-Jau

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9422530/laurence-camoin-jau-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63

papers

2,580

citations

20

h-index

50

g-index

81

ext. papers

2,989

ext. citations

5.2

avg, IF

4.31

L-index

#	Paper	IF	Citations
63	Case series of massive direct oral anticoagulant ingestion - treatment and pharmacokinetics data.. <i>European Journal of Clinical Investigation</i> , 2022 , e13746	4.6	0
62	F-fluorodeoxyglucose positron emission tomography/computed tomography for the diagnosis of native valve infective endocarditis: A prospective study. <i>Archives of Cardiovascular Diseases</i> , 2021 , 114, 211-220	2.7	5
61	Infective endocarditis with neurological complications: Delaying cardiac surgery is associated with worse outcome. <i>Archives of Cardiovascular Diseases</i> , 2021 , 114, 527-536	2.7	1
60	Ultrastructure of a late-stage bacterial endocarditis valve vegetation. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 821-826	5.1	1
59	Statins potentiate the antibacterial effect of platelets on. <i>Platelets</i> , 2021 , 32, 671-676	3.6	1
58	Different pattern of the second outbreak of COVID-19 in Marseille, France. <i>International Journal of Infectious Diseases</i> , 2021 , 102, 17-19	10.5	8
57	Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients. <i>Reviews in Cardiovascular Medicine</i> , 2021 , 22, 1063-1072	3.9	3
56	Clinical validation of immunoassay HemosIL [®] AcuStar HIT-IgG (PF4-H) in the diagnosis of Heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 601-609	5.1	0
55	Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?. <i>Journal of Microbiology, Immunology and Infection</i> , 2021 , 54, 37-45	8.5	2
54	Single or triple positivity for antiphospholipid antibodies in "carriers" or symptomatic patients: Untangling the knot. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 3018-3030	15.4	1
53	Spondylodiscitis complicating infective endocarditis. <i>Heart</i> , 2020 , 106, 1914-1918	5.1	4
52	Antiplatelet Agents Have a Distinct Efficacy on Platelet Aggregation Induced by Infectious Bacteria. <i>Frontiers in Pharmacology</i> , 2020 , 11, 863	5.6	8
51	Comparison Between ESC and Duke Criteria for the Diagnosis of Prosthetic Valve Infective Endocarditis. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 2605-2615	8.4	13
50	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. <i>Travel Medicine and Infectious Disease</i> , 2020 , 36, 101791	8.4	162
49	Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting. <i>Frontiers in Medicine</i> , 2020 , 7, 599626	4.9	5
48	Natural history of COVID-19 and therapeutic options. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 1159-1184	5.1	41
47	Effect of antiplatelet agents on platelet antistaphylococcal capacity: An in vitro study. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105890	14.3	4

46	The distinct effects of aspirin on platelet aggregation induced by infectious bacteria. <i>Platelets</i> , 2020 , 31, 1028-1038	3.6	3
45	Heparin-Induced Thrombocytopenia in Severe COVID-19. <i>Circulation</i> , 2020 , 142, 1875-1877	16.7	41
44	A Novel Approach for Detecting Unique Variations among Infectious Bacterial Species in Endocarditic Cardiac Valve Vegetation. <i>Cells</i> , 2020 , 9,	7.9	3
43	Aspirin Effect on -Platelet Interactions During Infectious Endocarditis. <i>Frontiers in Medicine</i> , 2019 , 6, 2174.9	4.9	8
42	Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome. <i>Platelets</i> , 2019 , 30, 105-111	3.6	1
41	Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 465-473	15.4	6
40	Intracranial haemorrhage in infective endocarditis. <i>Archives of Cardiovascular Diseases</i> , 2018 , 111, 712-721	17	16
39	Rapid identification of microorganisms from platelet concentrates by matrix-assisted laser desorption ionization time-of-flight mass spectrometry after short-term incubation on liquid medium. <i>Transfusion</i> , 2018 , 58, 766-773	2.9	1
38	Comparing two blood culture systems for the detection of bacterial contamination in platelet concentrates. <i>Transfusion</i> , 2018 , 58, 2604-2610	2.9	1
37	Platelet Reactivity: Journey to the End of the Night. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 114	15.1	2
36	Cross-Reactivity Between Heparin and Danaparoid Antibodies in Cardiac Surgery. <i>Annals of Thoracic Surgery</i> , 2017 , 103, e9-e10	2.7	2
35	Thrombosis and antiphospholipid antibody syndrome during acute Q fever: A cross-sectional study. <i>Medicine (United States)</i> , 2017 , 96, e7578	1.8	15
34	Coronary events complicating infective endocarditis. <i>Heart</i> , 2017 , 103, 1906-1910	5.1	18
33	Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 2560-2570	5	32
32	In vitro detection of bacterial contamination in platelet concentrates by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry: a preliminary study. <i>Journal of Medical Microbiology</i> , 2017 , 66, 1523-1530	3.2	3
31	Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2016 , 220, 496-500	3.2	10
30	Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 702-7	7	17
29	Enhanced prevalence of plasmatic soluble MHC class I chain-related molecule in vascular pregnancy diseases. <i>BioMed Research International</i> , 2014 , 2014, 653161	3	4

28	Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 872-7	15.1	211
27	Biological efficacy and clinical safety of a second 600 mg loading dose of clopidogrel in elderly patients with high on-treatment platelet reactivity: a pilot study. <i>International Journal of Cardiology</i> , 2013 , 165, 200-1	3.2	1
26	A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity. <i>International Journal of Cardiology</i> , 2013 , 168, 4244-8	3.2	12
25	Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. <i>Thrombosis Research</i> , 2012 , 130, 70-4	8.2	9
24	Factor VIII:C levels in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. <i>International Journal of Gynecology and Obstetrics</i> , 2012 , 116, 258-9	4	1
23	Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 101-6	7	22
22	Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?. <i>Current Pharmaceutical Design</i> , 2012 , 18, 5392-401	3.3	0
21	Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. <i>Hospital Practice (1995)</i> , 2012 , 40, 104-17	2.2	1
20	High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 467-73	15.1	181
19	High levels of circulating leukocyte microparticles are associated with better outcome in acute respiratory distress syndrome. <i>Critical Care</i> , 2011 , 15, R31	10.8	55
18	Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes. <i>American Journal of Cardiology</i> , 2011 , 108, 1710-3	3	31
17	Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 410-1	7	14
16	Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 456-63	7	128
15	Level of adenosine diphosphate receptor P2Y12 blockade during percutaneous coronary intervention predicts the extent of endothelial injury, assessed by circulating endothelial cell measurement. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1024-31	15.1	19
14	Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1630-6	15.1	98
13	Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function polymorphism. <i>International Journal of Cardiology</i> , 2010 , 145, 165-6	3.2	10
12	Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients. <i>Thrombosis Research</i> , 2010 , 125, e167-70	8.2	18
11	Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , 2010 , 126, e147-9	8.2	36

10	Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy. <i>Platelets</i> , 2010 , 21, 503-7	3.6	27
9	Personalized antiplatelet therapy for coronary artery disease patients: is this the future?. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 1525-32	2.5	1
8	TRAIL/Apo2L mediates the release of procoagulant endothelial microparticles induced by thrombin in vitro: a potential mechanism linking inflammation and coagulation. <i>Circulation Research</i> , 2009 , 104, 943-51	15.7	65
7	Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. <i>American Journal of Cardiology</i> , 2009 , 103, 5-10	3	237
6	Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2009 , 104, 1511-5	3	73
5	Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. <i>American Journal of Cardiology</i> , 2008 , 101, 1088-93	3	174
4	Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 1404-11	15.1	467
3	A threshold of platelet reactivity for ischaemic events?. <i>European Heart Journal</i> , 2008 , 29, 2185-6; author reply 2187	9.5	
2	Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. <i>Blood</i> , 2007 , 110, 2432-9	2.2	146
1	Soluble MHC Class I chain-related molecule serum levels are predictive markers of implantation failure and successful term pregnancies following IVF. <i>Human Reproduction</i> , 2007 , 22, 2261-6	5.7	18